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Extracorporeal removal of toxins
Pallavi K. Tyagi1, James F. Winchester1 and Donald A. Feinfeld1
Holubek et al. reviewed data on extracorporeal removal (ECR) of toxins 
from the Toxic Exposure Surveillance System (TESS) from 1985 to 2005. 
Hemodialysis use increased, but hemoperfusion nearly disappeared. 
Lithium, ethylene glycol, salicylate, and, increasingly, acetaminophen still 
often necessitate hemodialysis; ECR for theophylline has disappeared. 
TESS data do not separate continuous renal replacement therapy from 
hemodialysis, and not all poisonings were reported in this system. 
Nonetheless, these trends are useful to the nephrology community.
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Extracorporeal removal (ECR) techniques 
used for clearance of toxins can be a criti-
cal step in the management of chemical 
or drug poisoning. The use of these tech-
niques for removal of toxins can be justi-
fied if there is evidence of severe toxicity 
and if the total-body elimination of the 
toxin can be increased by 30% or more 
by the extracorporeal technique.1 Large 
randomized controlled trials of ECR in 
toxicology are hard to come by and, for 
obvious reasons, difficult to perform. 
Specific extracorporeal techniques and 
their indications remain a matter of 
debate. Application of extracorporeal 
modalities requires a thorough knowledge 
of drug pharmacokinetics and of the tech-
niques available. The technology of choice 
for the removal of a particular toxin, how-
ever, may not be immediately available to 
physicians in clinical practice.
Holubek et al.2 (this issue) describe 
trends in the use of ECR for removal 
of toxins in the United States over a 
21-year period of poison-center data 
recorded in the Toxic Exposure Surveil-
lance System (TESS) database from 1985 
to 2005. TESS is a uniform data set of 
cases reported from poison centers in 
the United States. Categories of infor-
mation include the patient, caller, route 
of exposure, substance or substances, 
clinical picture, treatment, and medical 
outcomes. The trend was an increase in 
hemodialysis (HD) use with a decrease 
in hemoperfusion (HP) over the final 10 
years. This may be attributed to a change 
in the technology itself as well as a change 
in the profiles of drugs causing overdose. 
Improvement in HD technologies over 
the years, with use of newer synthetic 
membranes at greater blood flow rates, 
has resulted in drug elimination rates 
similar to that achieved through HP.3 HP 
cartridges are expensive and have limited 
shelf life, and some require sterilization. 
It is technically more difficult to perform, 
cannot correct the acid–base fluid and 
electrolyte abnormalities associated with 
intoxications, and can cause thrombocy-
topenia, leukopenia, and hypocalcemia. 
According to TESS data from 2004, only 
27 of the almost 2.5 million exposures 
reported to United States poison control 
centers were managed with charcoal HP.4 
Shalkham et al. reported the availability 
of charcoal HP cartridges in only approx-
imately one-third of hospitals receiving 
emergency patients in New York City, 
and only three in-hospital HD units had 
performed HP in the past five years, on 
three cases.5 The use of theophylline and 
barbiturate drugs, which were tradition-
ally removed by HP, has declined, lead-
ing to a decline in the use of HP for their 
elimination.6
The role of continuous renal replace-
ment therapy (CRRT), available since the 
late 1970s, in the treatment of poisoning 
is still under debate and is not currently 
reported in the TESS database. The use of 
continuous veno-venous hemofiltration 
(CVVH) and continuous veno-venous 
hemodiafiltration (CVVHD) have been 
reported in poisonings with salicylates, 
barium, lithium, carbamazepine, phe-
nobarbital, methanol, iodine, pilsicain-
ide, mercury, metformin, valproic acid, 
and tetramine. CVVH and CVVHD are 
considered continuous therapies because 
they are applied for a longer time (24–48 
hours) than HD (usually 4–6 hours). 
An advantage of CVVH and CVVHD 
is that they are better tolerated than HD 
in hemodynamically unstable patients. 
CVVH achieves solute clearance by con-
vection (solvent drag effect) through the 
membrane, with pore dimensions larger 
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than those of conventional HD mem-
branes. In CVVHD, diffusive transport 
of molecules is combined with filtration 
in order to increase the solute clearance. 
Drugs and chemicals must meet given 
criteria in order to reach a high extrac-
tion ratio, that is, low molecular weight, 
low volume of distribution, and weak 
protein binding. Compared with HD, 
the properties of the membranes used for 
CVVH and CVVHD allow the removal 
of poisons with higher molecular weights 
(up to 40,000 da for CVVH and CVVHD 
compared with less than 500 da for HD). 
However, the toxicokinetic requirements 
for an efficient toxin removal do not dif-
fer between the two techniques: small vol-
ume of distribution (<1 liter per kg), low 
endogenous clearance (<4 ml/min/kg), 
and an extraction ratio exceeding endog-
enous elimination.7
The phenomenon of rebound must be 
considered in the evaluation of removal 
of drugs. Depending on the volume of 
distribution of a particular drug, a large 
quantity may be protein bound or stored 
intracellularly, as in muscle or adipose 
tissue. After cessation of ECR, any drug 
removed from the extracellular space can 
have a concentration gradient that causes 
drugs to move from their intracellular 
stores to the extracellular space, leading 
to a rebound increase in the plasma levels. 
CRRT can prevent rebound because of its 
constant clearance of substances with the 
clinical advantage of preventing rebound, 
for example, of lithium.8 Disadvantages of 
CRRT include that it requires patients to 
be sedentary for a long period of time; the 
need for anticoagulation; and that it may 
not be available at many smaller hospitals. 
The debate over CRRT versus HD contin-
ues, and the decision should be made on 
a case-by-case basis, keeping in mind that 
one modality can be followed by the other 
should the clinical status of the patient 
warrant such change. In cases in which 
the blood level of the toxin is very high, 
HD would be the preferred treatment if 
the patient can tolerate it.9
Figure 1 shows the percentage of all 
ECR treatments that were performed for 
10 toxins during each of the four quin-
quennia reviewed by Holubek et al.2 
Lithium, ethylene glycol, and salicylate 
remained the major toxins for which HD 
was performed, while ECR for acetami-
nophen and valproic acid poisoning has 
increased dramatically in recent years 
(Figure 1a), reflecting their increased use 
and hence likelihood of overdose. While 
theophylline and isopropanol have largely 
disappeared as indications for ECR (Fig-
ure 1b), HD and even HP continue to be 
used to treat ethanol poisoning.
Since 1989, acetaminophen has been the 
sixth most common reason for HD, and 
in 2001 it became the fifth most common 
exposure, replacing theophylline. Toxic 
exposures to acetaminophen (paraceta-
mol) have increased in other countries 
as well. In November 2003, paracetamol 
was made available in non-pharmacy 
outlets in Norway. In 2004, there was a 
considerable increase in inquiries to poi-
son centers regarding acute and chronic 
paracetamol exposures. The number of 
severe paracetamol exposures presented 
to poison centers nearly doubled from 
2003 to 2006.10 The Swedish Poisons 
Information Centre has observed a con-
tinuously increasing number of inquiries 
related to paracetamol overdose in adoles-
cents and young women.11 Although the 
possible benefit in terms of toxin removal 
from HD or HP late in acetaminophen 
poisoning has been questioned, a series of 
patients dialyzed more than 14 hours after 
ingestion of the drug had a smaller rise in 
hepatic enzymes than those with a similar 
overdose who were not dialyzed.12
The data of Holubek et al.2 were col-
lected from the TESS database, which 
has a number of limitations. Reporting to 
TESS is not regulated or required; instead, 
callers are seeking diagnostic or treatment 
assistance or information. As a result, the 
incidence of certain subsets of poisoning 
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Figure 1 | Trends in toxin-removal treatments. (a) Percentage of treatments reported for toxins 
with increasing use of ECR.2 (b) Percentage of treatments reported for toxins with decreasing or 
steady use of ECR.2 APAP, acetaminophen.
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is underreported in TESS, most notably 
substance abuse and poisoning fatalities. 
During the quinquennium 1985–1990, 
about one-fifth of the calls to poison cent-
ers were not included in TESS,4 so the 
trends in the report might not be as robust 
as they might have been if data collection 
had been more universal. TESS data are 
collected during telephone consultations; 
thus, bedside confirmation and data col-
lection are not necessarily conducted by 
specialists in poison information. How-
ever, because calls are initiated by the 
general public, health-care professionals, 
and emergency first responders, the data 
collected provide a broader narrative of 
poisoning exposures than those from 
traditional health-care databases. Data 
quality may improve as data are collected 
and documented by specialists in poison 
information during the evaluation of the 
exposure and determination of the poten-
tial toxicity and therapeutic needs. It is 
also worth bearing in mind that the trend 
of the use of ECR in the United States may 
not necessarily reflect trends in Europe 
and the rest of the world.
Newer techniques for removal of toxins, 
such as Molecular Adsorbent Recirculat-
ing System (MARS), although still not 
widely available, may eventually become 
more common and replace HD as the 
modality of choice for removal of certain 
toxins. Efficacy of MARS in the removal 
of protein-bound drugs such as pheny-
toin, diltiazem, and theophylline has been 
described in case reports, but its availabil-
ity remains limited.
The epidemiological trend of extracor-
poreal toxin removal in the United States 
has been changing, as has the profile of 
drugs removed by these techniques. With 
the use of newer techniques and change in 
drugs used in medical therapy, the trends 
will continue to evolve, with nephrologists 
playing a central role in the use of these 
therapeutic modalities.
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Interstitial fibrosis:  
tubular hypothesis  
versus glomerular hypothesis
Erik I. Christensen1 and Pierre J. Verroust1
The pathogenesis of renal interstitial fibrosis leading eventually to renal 
failure is highly debatable. Whereas the so-called tubular hypothesis, 
involving an increased tubular uptake of potentially toxic substances 
that induce a variety of cytokines, growth factors, and profibrogenic 
factors, is based to a large extent on cell-culture studies, the glomerular 
hypothesis is based mainly on careful morphological observations. 
Unraveling the pathways appears to be extremely complex, but in vivo 
studies appear to offer the most reliable results.
Kidney International (2008) 74, 1233–1236. doi:10.1038/ki.2008.421
Most if not all glomerular diseases involv-
ing extracapillary injury progressively 
develop extensive fibrotic processes, lead-
ing to nephron destruction and terminal 
renal failure. Two hypotheses have been 
put forward to account for this evolution. 
The first proposes that the primary event 
is tubular: the increased amount of protein 
that gains access to the proximal tubule, 
which results in increased protein traffick-
ing in the proximal tubule cells, is toxic 
for the cells, thus triggering a number of 
inflammatory and fibrotic pathways. The 
second proposes that the primary event is 
glomerular: the formation of glomerular 
crescents leads to encroachment on the 
glomerular–tubular junction and subse-
quent tubular degeneration. Two recent 
studies provide additional data in this 
context.
Motoyoshi et al.1 (this issue) induced 
massive glomerular proteinuria in a 
mouse model, mating mosaic megalin 
kidney knockout mice with a transgenic 
mouse, NEP25, in which podocytes 
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